This project will attempt to define, then prevent, delay, or reverse alloimmunization to platelet transfusions. We will evaluate patients prior to transplantation for evidence of alloimmunization based on antibody testing and radioisotope platelet survivals. Nonalloimmunized patients will be randomized to receive routinely prepared blood products or into two study arms: platelet transfusions exclusively from single unrelated donors given sequentially or platelets and red cells depleted of leukocytes. We will compare transfusion requirements, response to platelet transfusions and the development of lymphocytotoxic and platelet antibodies in these three groups. Methods will be developed for ultraviolet irradiation (UVI) of blood products and the prevention of alloimmunization with these products will be studied. In selected patients with antibodies to platelets prior to transplant, plasma exchange will be performed to remove antibodies kinetics will be evaluated by comparison to a similar group of alloimmunized patients who are not plasma exchanged. If plasma exchange is successful, specific methods of removing antibodies by ex vivo immunoabsorption with whole platelets will be developed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-14
Application #
3816012
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications